KlearTrust

Overview

KlearTrust is a patient journey intelligence platform for life-sciences, payer, and provider stakeholders that need to operationalize real-world performance tracking. For pharma launch teams, the clearest use case is not generic commercial analytics; it is the operating layer behind value-based agreements, pharmaceutical warranties, cohort surveillance, and evidence-driven access programs.

The platform brings claims, clinical, pharmacy, and patient-reported data into a computable patient view, then uses event-driven logic to monitor therapy starts, adherence milestones, progression signals, adverse events, contract endpoints, alerts, and reconciliation workflows. That makes KlearTrust most relevant when the buyer needs a shared source of truth for value demonstration across manufacturers, payers, and providers.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, KlearTrust is evaluated as patient journey intelligence platform for life-sciences, payer, and provider stakeholders that need to operationalize real-world performance tracking.

Capability	Buyer should compare	KlearTrust readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Core diligence point. KlearTrust markets a unified patient journey view, but buyers should confirm which source data is included in the agreement and which requires separate payer / provider / pharmacy access.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Focused strength. KlearTrust is strongest when RWE is tied to live program operations rather than one-off retrospective studies. Primary buyer fit. KlearTrust is built for programs where contract terms need patient-level tracking and transparent adjudication.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Major workflow layer. The public platform emphasizes event-driven alerts, collaboration, and reconciliation for complex multi-stakeholder programs.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Not the main buying reason for KlearTrust; validate only if the SOW includes provider, payer, and pharmacy network connectivity.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Not the main buying reason for KlearTrust; validate only if the SOW includes ai, nlp, and unstructured data extraction.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Emerging. Validate production use, model governance, and whether AI outputs are advisory or used in program logic.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Not the main buying reason for KlearTrust; validate only if the SOW includes reporting, dashboards, and data delivery.

Buyer Fit

• Procurement trigger: Include KlearTrust when a manufacturer needs patient journey intelligence to support RWE, market access, value-based contracting, or pharmaceutical warranty operations.
• Strongest users: HEOR, market access, brand, medical, evidence generation, and trade / payer teams working on specialty, rare-disease, cell / gene, neurology, or other high-cost therapies.
• Less direct fit: Pure HCP targeting, CRM, standalone adherence outreach, hub case management, or specialty pharmacy dispensing.
• Commercial fit: Expect a custom RFP around data integrations, endpoints, stakeholder roles, program logic, dashboards, alerts, reconciliation, and evidence deliverables.
• Commercial diligence: Named production references, data rights, endpoint governance, patient consent, payer/provider participation, implementation services, and AI controls.

Differentiators

• Value-based-program focus: KlearTrust’s public positioning is built around operationalizing outcomes-based agreements, pharmaceutical warranties, and risk-aligned contracts.
• Patient journey intelligence: The platform frames analytics around live patient events rather than static retrospective reporting.
• Neutral collaboration layer: KlearTrust positions itself as independent infrastructure connecting life sciences, payer, and provider stakeholders.
• Specialty-therapy relevance: CAR-Telligence, neurology, and high-cost therapy examples make the platform more relevant for complex specialty launches than for mass-market primary-care brands.
• Market access adjacency: KlearTrust sits close to payer evidence, access negotiation, and value demonstration, so it can complement HEOR / market-access strategy work.

RFP Questions

• Which data sources are included, and which require separate payer, provider, specialty pharmacy, registry, or manufacturer agreements?
• What value-based agreement or pharmaceutical warranty programs are currently live, and can KlearTrust provide references in the relevant therapeutic area?
• How are endpoints, eligibility, attribution, exclusions, discontinuation events, and financial reconciliation rules configured and audited?
• Which party acts on alerts: KlearTrust, the manufacturer, the payer, the provider, a hub vendor, or another operating partner?
• What patient consent, privacy, HIPAA, de-identification, and data-sharing controls apply to patient-level data?
• Which AI-assisted features are production-ready, and how are outputs validated before they affect program operations?
• How much of the implementation is software configuration versus consulting / services work?

Recent Activity

• 2025: KlearTrust appeared in AMCP 2025 exhibitor materials for patient journey intelligence and value-based program support.
• 2025: Public policy materials referenced pharmaceutical warranties and outcomes-based access models that align with KlearTrust’s stated use case.